Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

▤ Summary

On Monday, the clinical-stage San Diego biotech company announced it had added an experimental drug developed by Swiss pharma giant Novartis (NYSE: NVS) to its pipeline through a licensing deal. That compound, MAU868, is designed to target a protein associated with BK viral disease, an infection that occurs most often in people who have received a kidney or stem cell transplant. Recently, Amplyx has been studying a compound called fosmanogepix (APX001) as a treatment for candidemia—a serious infection of the blood stream caused by Candida, a strain of fungus. “It’s got a great overlap in terms of both how you conduct clinical trials in this space, and, ultimately, the types of physicians that will be prescribing both of these drugs,” she said in a phone interview. The company said successful treatment meant the patient was alive, with the fungus cleared from their blood, and received no other systemic antifungal therapies during the study.

▦ Linked Companies

Shareaholic

$1M to $5M